The global metastatic castration-sensitive prostate cancer treatment market is witnessing significant growth. This increase can be linked to factors such as an elevating population, rising prevalence of prostate cancer, and progresses in treatment choices. The market is also driven by enhanced knowledge about the disease and its treatment options.